Quick Facts
| Property | Value |
|---|---|
| Category | Anti-Inflammatory Peptide |
| Risk Level | Low/Moderate |
| Research Status | Strong Preclinical Research / Limited Human Research |
| Administration | Subcutaneous or Oral Research Use |
| Typical Frequency | Daily |
| Estimated Half-Life | Short-Acting (Reported) |
| Primary Research Interest | Gut Health / Inflammation / Immune Modulation |
This material is provided strictly for educational and informational purposes related to peptide research and experimental anti-inflammatory compounds. KPV is a biologically active peptide fragment capable of influencing inflammatory signaling pathways and gastrointestinal immune responses. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Summary
KPV is a naturally occurring tripeptide fragment derived from alpha-melanocyte stimulating hormone (α-MSH). Research interest in KPV primarily centers around its anti-inflammatory properties, gastrointestinal applications, immune modulation, and potential ability to influence inflammatory signaling pathways without many of the broader hormonal effects associated with its parent molecule.
Among currently discussed research peptides, KPV possesses a surprisingly substantial preclinical evidence base supporting anti-inflammatory and gastrointestinal applications. Much of the published literature focuses on intestinal inflammation, inflammatory bowel disease models, cytokine regulation, and epithelial immune responses.
What People Commonly Claim
- Improved gut health
- Reduced inflammatory signaling
- Histamine modulation
- Mast-cell stabilization
- Support for inflammatory skin conditions
- Enhanced recovery when stacked with regenerative peptides
- Potential MCAS-related benefits
What the Literature Actually Shows
- KPV demonstrates anti-inflammatory activity in multiple experimental models.
- Published research supports effects on intestinal inflammation and gastrointestinal immune regulation.
- KPV has demonstrated activity in inflammatory bowel disease research models.
- Oral administration has been successfully investigated in gastrointestinal research settings.
- Evidence for gut-related applications is substantially stronger than evidence for mast-cell, histamine, or MCAS-related applications.
- Human clinical research remains limited.
CKF Transparency Note: KPV is frequently discussed within peptide communities for histamine regulation, mast-cell stabilization, and inflammatory skin conditions. However, the strongest accessible literature currently supports gastrointestinal and anti-inflammatory applications rather than these broader claims. While mechanistic rationale exists for several proposed uses, much of the enthusiasm surrounding histamine-related applications presently exceeds the strength of the available published evidence.
2. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.0 mL
- Final Concentration: 5.00 mg/mL
At this concentration:
• 250 mcg = 0.050 mL (5.0 units)
• 1000 mcg = 0.200 mL (20.0 units)
3. Route of Administration
KPV is commonly researched through both subcutaneous and oral administration routes.
- Primary Route: SubQ Injection or Oral Research Use
- Preferred Timing: Flexible depending on protocol goals
- Administration Notes: Unlike many peptides, KPV possesses published literature supporting oral gastrointestinal applications in addition to injectable administration.
4. Typical Research Protocols
- Product Strength: 5.00 mg/mL
- Typical Delivered Amount: 250–1000 mcg daily
- Frequency: Daily
- Cycle Length: No standardized research protocol exists
- Special Notes: KPV is commonly stacked with compounds such as BPC-157, TB-500, and GHK-Cu in experimental recovery-focused protocols. However, standardized dosing strategies remain poorly established in the published literature. Research interest has primarily focused on inflammatory regulation, intestinal health, and immune-modulating effects.
5. Mechanism of Action
KPV is a biologically active tripeptide derived from the C-terminal region of α-MSH. Current evidence suggests that KPV influences inflammatory signaling pathways, cytokine regulation, epithelial immune responses, and gastrointestinal inflammatory activity.
- Anti-inflammatory signaling
- Cytokine regulation
- Gastrointestinal immune modulation
- Epithelial inflammatory pathway regulation
- Potential immune-response modulation
- α-MSH-derived signaling activity
Much of the published literature focuses on KPV’s effects within intestinal tissues and inflammatory bowel disease models, where reductions in inflammatory activity have been repeatedly observed.
6. Potential Benefits
- Potential support for gastrointestinal health
- Potential reduction of inflammatory signaling
- Support for intestinal immune regulation
- Potential inflammatory bowel disease research applications
- Possible support for inflammatory skin conditions
- Potential synergistic effects when paired with recovery-focused compounds
7. Potential Risks / Side Effects
Low/Moderate
- Injection-site irritation
- Digestive discomfort
- Fatigue
- Potential allergic reactions
- Limited long-term human safety data
- Limited data regarding chronic administration
8. Half-Life
KPV is generally described as a short-acting peptide, although precise pharmacokinetic data remain limited within the currently accessible literature.
Despite its likely short circulating duration, downstream effects on inflammatory signaling pathways and immune responses may persist considerably longer than measurable peptide concentrations.
Additional human pharmacokinetic research is needed to better characterize absorption, tissue distribution, and duration of action.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Severe immune disorders
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide compounds
- Use alongside immunomodulatory therapies without supervision
11. Further Study
Tier 1 — Essential Reading
- PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
- α-MSH Related Peptides: A New Class of Anti-Inflammatory and Immunomodulating Drugs?
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid–Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Tier 2 — Advanced Reading
- Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Effects in Murine Models of Inflammatory Bowel Disease
- Mechanism of KPV Action and a Role for MC3R Agonists
- Use of KPV Tripeptide for Dermatological Disorders
- Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration
Current Evidence Gaps
- Human clinical outcome data
- Long-term safety studies
- Mast-cell stabilization research
- Histamine modulation research
- MCAS-specific investigations
- Protocol standardization
- Pharmacokinetic characterization
12. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Gastrointestinal immunology literature
- Inflammation and cytokine signaling literature
- Peer-reviewed immune modulation journals
13. Last Reviewed
June 2026